Fulcrum Therapeutics, Inc. (FULC)
NASDAQ • Healthcare
Last close at September 11, 2026 at 20:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 29
in 46 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Fulcrum Therapeutics beat consensus on adjusted EPS in the second fiscal quarter of 2026, based on preliminary results reported on July 30, 2026, with adjusted EPS of -$0.21 versus the -$0.24 estimate, about +13.7%, up from -$0.28 a year ago. Net income was a loss of about $26.2 million, down 51.4% from a loss of $17.3 million a year earlier, while gross profit came in at negative $216,000 and operating income at roughly negative $19.9 million. Operating cash flow was negative $16.0 million. Consensus for the next period calls for EPS of -$0.13.
About Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. is a NASDAQ-listed healthcare biotechnology company that develops medicines for genetically defined and other rare diseases in the United States. In qualitative terms, it is a clinical-stage biotech business centered on targeted drug programs, with its current portfolio led by losmapimod and FTX-6058.
Today's Snapshot
FULC ended the day flat at 3.80, in line with a flat sector. Volume was about half of its usual level.
Trading Volume
Below 10d avg (1.4M)
814.7K
vs S&P 500 Today
Underperforming Market
-0.93%
Updated: September 11, 2026 at 20:26 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$3.82 - $6.56Sell
- RSI (14)47.18Neutral
- Stochastic %K (14, 3, 3)23.81Neutral
- MACD Level (12, 26)0.01Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.